BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its ...

In a big win for Cambridge-based Vertex Pharmaceuticals, the US Food and Drug Administration today approved the company’s drug Kalydeco (ivacaftor) to treat a rare form of cystic fibrosis. The drug is ...

- In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV 1 and superior in reducing sweat chloride compared to TRIKAFTA - - Approximately 3,800 people in Canada are now eligible for ...